恶性肿瘤不影响急性症状性髂股深静脉血栓形成药物机械溶栓的结局
单中心回顾性队列比较18例急性症状性髂股深静脉血栓形成患者(6例合并癌症、12例无癌症)行AngioJet药物机械溶栓的围手术期与短期结局,两组均实现静脉通畅恢复,癌症组支架置入更频繁(57.1% vs 13.3%,P=0.0316),两组均无复发性深静脉血栓、大出血或血栓后综合征。
要点
- 合并癌症与无癌症患者药物机械溶栓后短期结局无差异。
- 癌症组支架置入比例高于无癌症组(57.1% vs 13.3%,P=0.0316)。
- 两组均无复发性深静脉血栓、大出血或血栓后综合征。
核心结论
- 作者认为恶性肿瘤的存在不影响症状性深静脉血栓形成血管内溶栓治疗的短期结局,并指出需进一步随访评估长期结局。
研究设计与样本
- 单中心三级大学医疗机构的回顾性病历审查,纳入2013年12月至2016年12月连续接受AngioJet Power Pulse喷射联合血栓清除术的症状性髂股深静脉血栓形成患者,比较合并癌症与无癌症患者的结局。
- 共纳入18例连续患者共22条肢体:合并癌症6例患者(7条肢体),无癌症12例患者(15条肢体)。
主要发现
- 两组平均年龄分别为60.5±4.3岁与53.8±26.8岁(P=0.5593),女性分别占66.7%与25.0%(P=0.0878)。
- 下腔静脉受累率两组分别为57.1%与53.3%(P=0.8676),无显著差异。
- 两组均达到II级(50-94%溶解)和III级(95%完全溶解)血栓溶解并恢复静脉通畅,过夜导管定向溶栓很少使用。
- 癌症组支架置入比例高于无癌症组(57.1% vs 13.3%,P=0.0316)。
- 平均随访时间癌症组为3.42±4.41个月、无癌症组为4.50±2.43个月(P=0.5060),两组均无患者发生复发性深静脉血栓、大出血或血栓后综合征,无与血管内溶栓操作相关的死亡。
局限性
- 原文指出需进一步随访以评估长期结局。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer patients demonstrate increased risk for venous thromboembolism (VTE), VTE recurrence, and anticoagulation-associated bleeding. Pharmacomechanical thrombolysis (PMT) aand thrombectomy improves venous patency, venous valve function, and quality of life in patients with acute iliofemoral deep vein thrombosis (DVT). It remains unknown whether pharmacomechanical thrombolysis can be used safely in patients with active cancer. We hypothesized that perioperative and short-term outcomes of pharmacomechanical iliofemoral DVT thrombolysis would not differ between patients with cancer and those without cancer. METHODS: A retrospective chart review of consecutive patients with symptomatic iliofemoral DVT undergoing PMT by AngioJet Power Pulse spray and thrombectomy at a single tertiary care university institution between December 2013 and December 2016 was performed. Outcomes between patients with cancer and without cancer were compared. RESULTS: We identified 22 limbs in 18 consecutive patients: 6 patients (7 limbs) with cancer and 12 patients (15 limbs) without cancer. Between these groups, the mean age was 60.5 ± 4.3 vs. 53.8 ± 26.8 years, respectively (P = 0.5593), and females comprised 66.7% vs. 25.0%, respectively (P = 0.0878). No significant difference in inferior vena cava (IVC) involvement between the groups (57.1% vs. 53.3%, P = 0.8676) was noted. Grade II (50-94% lysis) and III (95% complete lysis) thrombus lysis with restoration of venous patency was achieved in both the groups. Overnight catheter-directed thrombolysis (CDT) was rarely used. Notably, stenting was more frequently employed in cancer patients than in those without cancer (57.1% vs. 13.3%, P = 0.0316). The mean duration of follow-up was 3.42 ± 4.41 months for the cancer group and 4.50 ± 2.43 months for the noncancer group (P = 0.5060). Overall outcomes were excellent as no patient in both the groups experienced recurrent DVT, major bleeding, or postthrombotic syndrome. There was no mortality associated with the endovascular thrombolysis procedures. CONCLUSIONS: The results of our study suggest that the presence of malignancy does not affect short-term outcomes of endovascular thrombolytic therapy in symptomatic DVT. Further follow-up is needed to evaluate long-term outcomes.
引用
- Yoon WJ, Halandras P, Aulivola B, et al. Malignancy Does not Affect Outcomes of Pharmacomechanical Thrombolysis in Acute Symptomatic Iliofemoral Deep Vein Thrombosis. Ann Vasc Surg. 2018. PMID: 29518515. doi:10.1016/j.avsg.2018.01.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。